About Vermillion (NASDAQ:VRML)
Vermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Diagnostics & Testing
- Sub-Industry: N/A
- Symbol: NASDAQ:VRML
- CUSIP: N/A
- Web: www.vermillion.com
- Market Cap: $83.68 million
- Outstanding Shares: 56,164,000
- 50 Day Moving Avg: $1.48
- 200 Day Moving Avg: $1.64
- 52 Week Range: $0.76 - $2.85
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: $3.05 million
- Price / Sales: 27.44
- Book Value: $0.08 per share
- Price / Book: 18.63
- EBITDA: ($10,500,000.00)
- Net Margins: -372.05%
- Return on Equity: -215.26%
- Return on Assets: -121.77%
- Debt-to-Equity Ratio: 0.34%
- Current Ratio: 3.21%
- Quick Ratio: 3.16%
- Average Volume: 49,137 shs.
- Beta: 2.52
- Short Ratio: 16.56
Frequently Asked Questions for Vermillion (NASDAQ:VRML)
What is Vermillion's stock symbol?
Vermillion trades on the NASDAQ under the ticker symbol "VRML."
How were Vermillion's earnings last quarter?
Vermillion, Inc. (NASDAQ:VRML) posted its quarterly earnings results on Wednesday, August, 9th. The company reported ($0.04) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.04). The business had revenue of $0.90 million for the quarter. Vermillion had a negative return on equity of 215.26% and a negative net margin of 372.05%. View Vermillion's Earnings History.
Where is Vermillion's stock going? Where will Vermillion's stock price be in 2017?
1 brokers have issued 12 month target prices for Vermillion's stock. Their predictions range from $1.75 to $1.75. On average, they anticipate Vermillion's share price to reach $1.75 in the next year. View Analyst Ratings for Vermillion.
Are investors shorting Vermillion?
Vermillion saw a increase in short interest during the month of September. As of September 15th, there was short interest totalling 982,035 shares, an increase of 27.9% from the August 31st total of 767,768 shares. Based on an average trading volume of 43,840 shares, the days-to-cover ratio is presently 22.4 days. Currently, 3.1% of the shares of the stock are sold short.
Who are some of Vermillion's key competitors?
Some companies that are related to Vermillion include BioDelivery Sciences International (BDSI), Concord Medical Services Holdings Limited (CCM), Vascular Biogenics (VBLT), Viralytics (VRACY), ConforMIS (CFMS), Ocular Therapeutix (OCUL), Summit Therapeutics PLC (SMMT), Invuity (IVTY), Redhill Biopharma (RDHL), Advaxis (ADXS), Osiris Therapeutics (OSIR), Adocia (ADOCY), Obalon Therptcs (OBLN), Conatus Pharmaceuticals (CNAT), Quorum Health Corporation (QHC), Adverum Biotechnologies (ADVM), Fluidigm Corporation (FLDM) and Nuvectra Corporation (NVTR).
Who are Vermillion's key executives?
Vermillion's management team includes the folowing people:
- James T. LaFrance, Chairman of the Board
- Valerie Barber Palmieri, President, Chief Executive Officer
- Fred Ferrara, Chief Operating Officer
- Donald G. Munroe Ph.D., Senior Vice President - Business Development, Chief Scientific Officer
- Eric J. Schoen, Chief Accounting Officer, Vice President - Finance
- James S. Burns, Independent Director
- Veronica G. H. Jordan Ph.D., Independent Director
- David R Schreiber, Independent Director
- Carl Severinghaus, Independent Director
- Eric K. Varma M.D., Independent Director
How do I buy Vermillion stock?
Shares of Vermillion can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vermillion's stock price today?
MarketBeat Community Rating for Vermillion (NASDAQ VRML)MarketBeat's community ratings are surveys of what our community members think about Vermillion and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Vermillion stock can currently be purchased for approximately $1.49.
Consensus Ratings for Vermillion (NASDAQ:VRML) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Buy Rating|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$1.75 (17.45% upside)|Consensus Price Target History for Vermillion (NASDAQ:VRML)
Analysts' Ratings History for Vermillion (NASDAQ:VRML)
(Data available from 10/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|8/30/2017||Canaccord Genuity||Reiterated Rating||Buy||$2.50 -> $1.75||Low|
Earnings History for Vermillion (NASDAQ:VRML)Earnings History by Quarter for Vermillion (NASDAQ VRML)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/9/2017||Q2 2017||($0.04)||($0.04)||$0.90 million||View||Listen|
|5/18/2017||Q1 2017||($0.04)||($0.05)||$0.73 million||View||N/A|
|3/24/2016||Q415||($0.10)||$1.20 million||$0.36 million||View||Listen|
|11/12/2015||Q315||($0.10)||($0.10)||$0.57 million||$0.33 million||View||Listen|
|8/13/2015||Q215||($0.08)||($0.11)||$1.50 million||$535.00 million||View||Listen|
|5/11/2015||Q115||($0.10)||($0.10)||$0.81 million||$0.95 million||View||Listen|
|3/25/2015||Q414||($0.08)||($0.11)||$1.59 million||$1.57 million||View||Listen|
|11/14/2013||Q3||($0.10)||$319.00 million||$330.00 million||View||Listen|
|8/14/2013||Q2 2013||($0.11)||$0.32 million||$0.23 million||View||Listen|
|5/15/2013||Q1 2013||($0.15)||($0.17)||$0.30 million||$0.33 million||View||Listen|
Earnings Estimates for Vermillion (NASDAQ:VRML)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Vermillion (NASDAQ:VRML)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Vermillion (NASDAQ:VRML)
Insider Ownership Percentage: 3.67%Insider Trades by Quarter for Vermillion (NASDAQ:VRML)
Institutional Ownership Percentage: 35.57%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/16/2017||Valerie Barber Palmieri||Insider||Buy||694||$1.44||$999.36|| |
|9/15/2017||Valerie Barber Palmieri||Insider||Buy||719||$1.39||$999.41|| |
|8/23/2017||Valerie Barber Palmieri||Insider||Buy||768||$1.30||$998.40|| |
|5/17/2017||Valerie Barber Palmieri||Insider||Buy||555||$1.80||$999.00|| |
|2/17/2017||Larry N Feinberg||Insider||Buy||617,731||$1.40||$864,823.40|| |
|2/13/2017||Eric Schoen||SVP||Buy||3,347||$1.40||$4,685.80|| |
|2/13/2017||Jack W Schuler||Major Shareholder||Buy||974,081||$1.40||$1,363,713.40|| |
|2/13/2017||Valerie Barber Palmieri||CEO||Buy||10,042||$1.40||$14,058.80|| |
|2/13/2017||Veronica Gh Jordan||Director||Buy||6,695||$1.40||$9,373.00|| |
|1/28/2016||Jack W Schuler||Major Shareholder||Buy||1,493||$1.60||$2,388.80|| |
|1/25/2016||Jack W Schuler||Major Shareholder||Buy||3,700||$1.57||$5,809.00|| |
|1/21/2016||Jack W Schuler||Major Shareholder||Buy||30,700||$1.46||$44,822.00|| |
|1/19/2016||Jack W Schuler||Major Shareholder||Buy||57,749||$1.45||$83,736.05|| |
|1/15/2016||Jack W Schuler||Major Shareholder||Buy||8,400||$1.56||$13,104.00|| |
|7/14/2015||Larry N Feinberg||Insider||Buy||512,043||$1.96||$1,003,604.28|| |
|12/23/2014||Jack W Schuler||Major Shareholder||Buy||1,288,339||$1.44||$1,855,208.16|| |
|12/23/2014||Larry N Feinberg||Insider||Buy||972,222||$1.44||$1,399,999.68|| |
|12/19/2014||Peter S Roddy||Director||Buy||16,502||$1.44||$23,762.88|| |
|11/21/2014||Valerie Barber Palmieri||COO||Buy||3,500||$1.51||$5,285.00|| |
|11/20/2014||James T Lafrance||Insider||Buy||27,907||$1.44||$40,186.08|| |
|11/20/2014||Valerie Barber Palmieri||COO||Buy||30,000||$1.44||$43,200.00|| |
|11/19/2014||James T Lafrance||Insider||Buy||41,615||$1.43||$59,509.45|| |
|11/18/2014||Eric Schoen||CAO||Buy||5,000||$1.42||$7,100.00|| |
|11/20/2013||William B Creech||VP||Buy||2,000||$2.33||$4,660.00|| |
|6/11/2013||William B Creech||VP||Buy||10,000||$3.18||$31,800.00|| |
Headline Trends for Vermillion (NASDAQ:VRML)
Latest Headlines for Vermillion (NASDAQ:VRML)
Loading headlines, please wait.
Vermillion (VRML) Chart for Monday, October, 23, 2017